New hope for tough leukemia: Triple-Drug attack trial launches
Disease control
Not yet recruiting
This early-phase study tests whether adding a new drug called eganelisib to two standard AML treatments (venetoclax and azacitidine) is safe and helps control the disease. It enrolls 48 adults with AML that has returned or not responded to prior therapy. The main goal is to find …
Phase: PHASE1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated May 13, 2026 16:00 UTC